Medication safety in patients treated with new oral anticancer agents: a prospective randomized investigation on the impact of intensified clinical pharmaceutical/clinical pharmacological care on patient safety and patient reported outcome
Not Applicable
- Conditions
- all types of cancer treated with an oral anticancer agent
- Registration Number
- DRKS00013271
- Lead Sponsor
- Apotheke des Universitätsklinikums Erlangen; Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie der FAU Erlangen-Nürnberg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 202
Inclusion Criteria
Initiation of therapy with an oral anticancer agent, cancer diagnosis, adult patient, planned duration of therapy / estimated lifespan of at least 4 months, ability to complete questionnaires
Exclusion Criteria
Prolonged inpatient stay and concomitant i.v. chemotherapy with classical cytostatic drugs, lack of german language skills, cognitive impairment, non-consenting patients, patients who are not able to take their medicine on their own, pregnant / lactating women, missing written consent
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method drug related problems (DRP) (number of DRP per patient after 12 weeks), satisfaction with anticancer therapy (TSQM VII questionnaire after 12 weeks)
- Secondary Outcome Measures
Name Time Method patient knowledge (SIMS-D questionnaire after 12 weeks), adherence (MARS-D questionnaire after 12 weeks), quality of life (QLQ-C30 questionnaire after 12 weeks)